Evidence map›Paper›PMID 24899198›Full record

ArticleJournal of virology2014

ISG15 functions as an interferon-mediated antiviral effector early in the murine norovirus life cycle.

Marisela R Rodriguez, Kristen Monte, Larissa B Thackray, Deborah J Lenschow

Open access · bronzeAbstract read
In one paragraph

Article in Journal of virology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 54 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Marisela R RodriguezDepartment of Internal Medicine, Washington University School of Medicine, St. Louis, Missouri, USA.
Kristen MonteDepartment of Internal Medicine, Washington University School of Medicine, St. Louis, Missouri, USA.
Larissa B ThackrayDepartment of Infectious Disease, Washington University School of Medicine, St. Louis, Missouri, USA.
Deborah J LenschowDepartment of Internal Medicine, Washington University School of Medicine, St. Louis, Missouri, USA Department of Infectious Disease, Washington University School of Medicine, St. Louis, Missouri, USA dlenscho@dom.wustl.edu.
Washington University in St. Louis · US

Funding

Viral Discovery in Rheumatoid ArthritisP30AR048335 · NIAMS · WASHINGTON UNIVERSITY · PI YOKOYAMA, WAYNE M. · 2001 to 2015
$8.9M
TRAINING IN THE IMMUNOLOGY OF RHEUMATIC DISEASEST32AR007279 · NIAMS · WASHINGTON UNIVERSITY · PI Megan Anne Cooper, Deborah J Lenschow · 1986 to 2026
$6.0M
NIAMS NIH HHS NRSA T32 AR07279-30NIAMS NIH HHS P30 AR048335NIAMS NIH HHS T32 AR007279PHS HHS R01 A1080672
6 · The paper itself

Abstract

unlabelledHuman noroviruses (HuNoV) are the leading cause of nonbacterial gastroenteritis worldwide. Similar to HuNoV, murine noroviruses (MNV) are enteric pathogens spread via the fecal-oral route and have been isolated from numerous mouse facilities worldwide. Type I and type II interferons (IFN) restrict MNV-1 replication; however, the antiviral effectors impacting MNV-1 downstream of IFN signaling are largely unknown. Studies using dendritic cells, macrophages, and mice deficient in free and conjugated forms of interferon-stimulated gene 15 (ISG15) revealed that ISG15 conjugation contributes to protection against MNV-1 both in vitro and in vivo. ISG15 inhibited a step early in the viral life cycle upstream of viral genome transcription. Directly transfecting MNV-1 RNA into IFN-stimulated mouse embryonic fibroblasts (MEFs) and bone marrow-derived dendritic cells (BMDC) lacking ISG15 conjugates bypassed the antiviral activity of ISG15, further suggesting that ISG15 conjugates restrict the MNV-1 life cycle at the viral entry/uncoating step. These results identify ISG15 as the first type I IFN effector regulating MNV-1 infection both in vitro and in vivo and for the first time implicate the ISG15 pathway in the regulation of early stages of MNV-1 replication. IMPORTANCE: Type I IFNs are important in controlling murine norovirus 1 (MNV-1) infections; however, the proteins induced by IFNs that restrict viral growth are largely unknown. This report reveals that interferon-stimulated gene 15 (ISG15) mitigates MNV-1 replication both in vitro and in vivo. In addition, it shows that ISG15 inhibits MNV-1 replication by targeting an early step in the viral life cycle, MNV-1 entry and/or uncoating. These results identify ISG15 as the first type I IFN effector regulating MNV-1 infection both in vitro and in vivo and for the first time implicate the ISG15 pathway in the regulation of viral entry/uncoating.

Indexed as

AnimalsAntiviral AgentsCell LineCytokinesDendritic CellsFibroblastsGenome, ViralInterferon Type ILife Cycle StagesMacrophagesMiceMice, Inbred C57BLNorovirusTranscription, GeneticUbiquitinsVirus ReplicationAntiviral AgentsCytokinesG1p2 protein, mouseInterferon Type IUbiquitins

Identifiers

PMID24899198
PMCPMC4136287
OpenAlexW1999856423

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.